Figure 5.

Intratumoral STING agonist modeling in autologous humanized mice. Palpable tumors of equivalent size in both groups were treated intratumorally with either PBS control or ML-RR-CDA (STING agonist) at 20 μg per injection and the tumor growth monitored. The experiment was repeated twice with 4–5 mice per group. At the completion of experiment the tumor was harvested and stained with human CD8, IFNγ, and DAPI counterstain (right panels). The bar scale is 100 μ (adopted from Fu, et.al., 2016).